Lakeland Regional Medical Center

(863) 687-1100

Lakeland Regional Cancer Center
Lakeland Regional Cancer Center
Lakeland Regional Cancer Center

Print Page

Breast Cancer

Clinical Trial # 20110147:

  • Naproxen or Loratadine for bone pain associated with Pegfilgrastim treatment for Breast Cancer patients stages I, II or III.
  • Participants must be newly diagnosed, no prior chemotherapy, and have at least four (4) cycles of chemotherapy planned (but they can not be weekly treatments).
  • Exclusions include, but are not limited to: Another cancer within the past five (5) years, current chronic pain, bleeding disorders, chronic use of NSAIDS or steroids, prior use of G-CSF or chemotherapy. 

Clinical Trial #A221102:

  • Testosterone versus placebo subcutaneously 2x for post menopausal women who are receiving Anastrozole or Letrozole and have side effects causing pain 5 or greater out of a scale of 10.
  • ER and PR status would both have to be positive with at least a 30% positivity.
  • BMI required to be between 18-32 kg/m2.

Clinical Trial #B-43:

  • Radiation with or without Herceptin after surgery for women with Her 2 positive Ductal Carcinoma in situ.
  • Participants can have Ductal Carcinoma in situ and Lobular Carcinoma in situ, but not invasive. Lumpectomy surgery only.  Participation must begin prior to the 120th day from surgery.
  • Exclusions  include, but are not limited to: Contralateral breast cancer, multicentric disease, partial breast radiation, active cardiac disease, uncontrolled blood pressure, history of CHF, cardiomyopathy or a recent MI.

Clinical Trial E-1Z11:

  • Lab study for post menopausal women who are currently on Anastrozole (Arimidex). 
  • Patients who areStage I-III who are ER and/or PR positive  and have completed adjuvant chemotherapy may qualify. 
  • Exclusions include, but are not limited to  those who have chronic analgesic use, have had a DVT or PE in the last five years and have a pain score of four or higher out of ten.

© 2014 Lakeland Regional Medical Center